
北美临床试验市场预测至 2028 年 - 区域分析 - 按研究设计(介入、观察和扩大访问)、阶段(第一阶段、第二阶段、第三阶段和第四阶段)和适应症(自身免疫/炎症、疼痛管理) 、肿瘤学、中枢神经系统疾病、糖尿病、肥胖、心血管等)
No. of Pages: 132 | Report Code: BMIRE00029014 | Category: Life Sciences
No. of Pages: 132 | Report Code: BMIRE00029014 | Category: Life Sciences
制药行业是全球研发最密集的行业之一。随着制药公司热衷于确保研发实现其预期目标,药品的价值变得越来越重要。在过去十年中,每年批准的新药数量也有所增加。我们正在努力提高满足患者需求的有效性和效率。美国是研发投资的领先国家,在过去十年中生产了世界上一半以上的新分子。美国占 2014 年至 2019 年新上市新药销售额的 62.3%。研发是制药公司业务的重要组成部分,因为它使制药公司能够为具有巨大医疗和商业潜力的各种治疗应用开发新分子。
研发支出用于发现、检验和生产新产品;预付款;改善现有成果;并在推出前证明产品功效和法规合规性。研发投资根据临床试验的需要和要求而有所不同。成本包括材料、使用的用品和工资,以及开发质量控制的成本。
北美临床试验市场分为美国、加拿大和墨西哥。美国是最大且增长最快的临床试验市场。该地区的市场增长归功于美国作为领先的临床研究目的地以及公司为临床试验应用提供的创新服务。
美国已成为领先的临床研究目的地。近一半的临床试验是在美国进行的。此外,由于成熟的医疗基础设施、快速的审批时间表、有利的监管框架以及全球公认的临床试验生成数据,大多数制药研究公司更愿意在美国进行临床试验。世界卫生组织 (WHO) 报告指出,2021 年美国登记的临床试验数量最多(157,618 项)。
北美国临床试验市场细分
北美临床试验市场分为阶段、研究设计、适应症和国家。
根据阶段,北美临床试验市场分为 I 期、II 期、III 期和 IV 期。 2022年,III期临床试验市场份额最大。
根据研究设计,北美临床试验市场分为介入型、观察型和扩展型。使用权。 2022 年,介入细分市场占据北美最大的临床试验市场份额。
根据适应症,北美临床试验市场分为自身免疫/炎症、疼痛管理、肿瘤学、中枢神经系统疾病、糖尿病、肥胖、心血管等。 2022 年,肿瘤学领域占据北美临床试验市场份额最大。
按国家划分,北美临床试验市场分为美国、加拿大、和墨西哥。 2022 年,美国在北美临床试验市场份额中占据主导地位。
Charles River Laboratories International Inc、ICON Plc、IQVIA Holdings Inc、IXICO Plc、Laboratory Corp of America Holdings 、Parexel International Corp、SGS SA、Syneos Health Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd. 是北美临床试验市场上的一些领先公司。
Strategic insights for North America Clinical Trials involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 27,322.28 Million |
Market Size by 2028 | US$ 36,818.15 Million |
Global CAGR (2022 - 2028) | 5.1% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 研究设计
|
Regions and Countries Covered | 北美
|
Market leaders and key company profiles |
The regional scope of North America Clinical Trials refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Clinical Trials Market is valued at US$ 27,322.28 Million in 2022, it is projected to reach US$ 36,818.15 Million by 2028.
As per our report North America Clinical Trials Market, the market size is valued at US$ 27,322.28 Million in 2022, projecting it to reach US$ 36,818.15 Million by 2028. This translates to a CAGR of approximately 5.1% during the forecast period.
The North America Clinical Trials Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Clinical Trials Market report:
The North America Clinical Trials Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Clinical Trials Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Clinical Trials Market value chain can benefit from the information contained in a comprehensive market report.